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The role and challenges of cluster randomised trials for 
global health
Louis Dron, Monica Taljaard, Yin Bun Cheung, Rebecca Grais, Nathan Ford, Kristian Thorlund, Fyezah Jahan, Etheldreda Nakimuli-Mpungu, 
Denis Xavier, Zulfiqar A Bhutta, Jay J H Park, Edward J Mills
Evaluating whether an intervention works when trialled in groups of individuals can pose complex challenges for 
clinical research. Cluster randomised controlled trials involve the random allocation of groups or clusters of 
individuals to receive an intervention, and they are commonly used in global health research. In this paper, we 
describe the potential reasons for the increasing popularity of cluster trials in low-income and middle-income 
countries. We also draw on key areas of global health research for an assessment of common trial planning practices, 
and we address their methodological shortcomings and pitfalls. Lastly, we discuss alternative approaches for 
population-level intervention trials that could be useful for research undertaken in low-income and middle-income 
countries for situations in which the use of cluster randomisation might not be appropriate.
Introduction
Use of robust randomised clinical trial (RCT) evaluation 
is crucial to determine which interventions would be 
useful for public health or clinical care.1,2 Certain 
interventions are delivered at a population level or at a 
group level, and these interventions can result in 
changes to group behaviours, leading to large scale 
population-level effects.3 The cluster RCT design (herein, 
cluster trial) is a specific trial design that is used to 
evaluate interventions delivered at a group level.4 In 
cluster trials, whole groups of structured collections of 
individuals or health system service delivery platforms, 
such as facilities, are randomly assigned to receive 
interventions, and these groups are referred to as 
clusters. Examples of clusters include communities, 
health clinics, or schools. In contrast to the individual 
RCT, in which the group allocation of interventions is 
determined by randomisation of individual participants, 
cluster trials randomly assign interventions to a whole 
cluster of individuals. Interventions themselves can be 
administered at a cluster level (eg, mosquito egg traps5) 
or at an individual level (eg, vaccinations6). In cluster 
trials, outcomes can be measured at a cluster level6 or at 
an individual level.7
There is an increasing popularity of the use of cluster 
trials in low-income and middle-income countries 
(LMICs).8 There have been many successful high-profile 
trials that have used a cluster trial design, and many of 
the design features of cluster trials lend themselves well 
to priority areas of research set in LMICs. Despite the 
increasing use of this design, there can be methodological 
and interpretational challenges. Cluster trials are 
complex due to the interplay between the similarities of 
individual participants within a cluster and the 
differences between clusters.9,10 Because outcomes of 
individuals within the same cluster are correlated, 
standard methods for design and analysis of individual 
RCTs do not suffice for cluster trials. Furthermore, 
because special considerations are required when 
designing and analysing cluster trials, there have been 
great efforts towards unifying and improving the 
standards of the design and analysis interpretation of 
cluster trials.9,11 However, some evaluations have 
identified several design and interpretational challenges 
to cluster trials that often arise due to inadequate 
planning.12–14
In this third paper of the Series, we first discuss 
the attributes of cluster trials in the context of global 
health research, followed by specific challenges that 
are associated with planning and implementing such 
attributes in LMICs. We then draw on examples of 
Key messages
• When interventions can be delivered at the individual level, 
there should be clear scientific justifications for cluster 
randomisation. Cluster trials are ideal for evaluating 
interventions that can only be delivered at the level of 
clusters or interventions that have shown to be effective 
under controlled conditions in individually randomised 
clinical trials that require further evaluation of whether 
they work at scale. In appropriate situations, cluster trials 
can be better tailored for implementation science than 
individually randomised controlled trials.
• During the trial planning stage, it is difficult to estimate 
clustering effects (eg, intracluster correlation) and other 
key assumptions required in traditional trial designs (eg, 
event rates and treatment effects), so it might be useful to 
plan for multi-stage approaches by use of interim data to 
estimate key trial parameters and reassess the sample size.
• When there are only a small number of clusters available 
for randomisation, the use of covariate constrained 
allocation methods might be useful, given that baseline 
imbalance between intervention and control groups might 
be difficult to avoid with simple randomisation.
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cluster trials implemented across key global health 
research areas, such as maternal, newborn, and child 
health (MNCH), malaria, and water, sanitation, and 
hygiene (WASH), to assess the current cluster trial 
planning practices in LMICs. Lastly, we describe 
examples of high-quality and innovative LMIC-based 
cluster trials, (panels 1–3) and we outline alternative 
approaches and supplementary methodologies to 
Panel 1: Summary of the MORDOR trial: a cluster trial with planned interim analysis on mass distribution of azithromycin for 
child mortality in sub-Saharan Africa
MORDOR is a placebo-controlled cluster trial that has been 
undertaken in Malawi, Tanzania, and Niger, to evaluate the 
efficacy of biannual mass distribution of oral azithromycin on all-
cause mortality for children aged 1–59 months.7 Before this study, 
oral azithromycin had shown effectiveness against trachoma and 
other infectious diseases, such as malaria, diarrhoea, and 
pneumonia.15–20 Because mass distribution of azithromycin cannot 
be tested in individually randomised clinical trials, due to risk of 
contamination between groups, a cluster randomised trial design 
was ideal to answer this research question.
The investigators of MORDOR prespecified plans for an interim 
analysis for stopping the trial early on the basis of superiority 
and futility. One interim analysis was implemented after 
mortality data became available for a third of the person-years 
in the study, with each country having contributed at least 
6 months of follow-up for half or more of the clusters in each 
country. An α value of 0·001 was used as the decision rule for 
stopping the trial early for superiority, with an α value of 0·049 
used to determine statistical significance at the final analysis. 
The decision rule for stopping the trial early for futility was 
prespecified as 20% or lower conditional power, to detect a 
25% treatment effect. Because the decision rules for stopping 
the trial early were not met, this cluster trial did not stop after 
the interim analysis was done.
In the MORDOR trial, 1533 communities (clusters) were 
randomly assigned to receive either mass distribution of oral 
azithromycin or placebo on study completion, 
with 190 238 children enrolled (323 302 person-years 
monitored). This trial showed large mortality reduction benefits 
with mass distribution of azithromycin; the azithromycin group 
had a 13·5% (95% CI 6·7–19·8) lower child mortality risk 
compared with the placebo.7
Panel 2: Summary of the PASTAL trial: an adaptive multiarm, multi-stage cluster trial for HIV testing and linkage to care 
PASTAL is a phase 2 adaptive multiarm, multi-stage cluster trial 
in Malawi that evaluated the effects on the uptake of HIV 
testing and subsequent HIV services by male partners of 
pregnant women accessing antenatal clinics.21,22 This trial 
started with one control arm and five intervention arms. As the 
standard of care, the pregnant women within clusters 
randomised to the control group received a personalised 
invitation letter to a male-friendly HIV clinic that was addressed 
to their male partners, and this clinic would offer HIV testing, 
linkage to care (if shown to be HIV-positive), and pregnancy 
health education. The clusters randomly assigned to one 
intervention group would receive the standard of care and 
two self-test kits; those assigned to two other intervention 
groups would receive standard of care, two self-test kits, and a 
conditional financial incentive for the amount of either 
US$3 (one group) or $10 (in the other group) for male partners 
who self-tested and attended the HIV clinic. Another 
intervention group received standard of care, two self-test kits, 
and conditional lottery entry, with a 10% chance of 
winning $30; and the final intervention arm received standard 
of care, two self-test kits, and a telephone call reminder of their 
clinical appointments.
Stopping the trial early was only considered for futility reasons, 
and not for superiority. At the first stage, the outcomes 
reported in each intervention group were compared with the 
control group, and the intervention group was considered to be 
dropped from the trial if the pairwise comparison showed a 
p value that exceed 0·20. An independent data safety 
monitoring board used this p-value threshold and 
considerations of cost and safety to remove intervention 
groups after the interim analysis at the first stage. The data 
safety monitoring board stopped the interventional approach 
that included a conditional lottery entry after the interim 
analysis showed a p value of 0·211. The intervention that 
consisted of standard of care and self-test kits only was 
continued to the second stage, despite meeting the threshold 
for stopping, due to the local policy makers wanting to test this 
approach in the subsequent stage. In addition to stopping the 
trial early, sample size reassessment was used to re-calculate the 
sample size required for the second (final) stage of the trial. The 
empirical estimates from the interim analysis were 
used to re-calculate the sample size required under the 
constraints of 10% family-wise type I error rate and 
80% statistical power.
At the end of the trial, there were 71 antenatal clinics (clusters) 
involved, with 2349 women randomly assigned (six clusters per 
arm in the first stage and seven clusters per arm in the second 
stage, after dropping the arm with the lottery). Compared with 
control clusters in which 17·4% of the male partners were tested 
for HIV, a higher proportion of male individuals met the 
primary endpoint in all intervention arms. For instance, among 
the intervention arm with conditional financial incentives of $3 
or $10, which had the largest effect sizes, higher adjusted risk 
ratios of 3·01 (95% CI 1·63–5·57; for the $3 group) and 3·72 
(1·85–7·48; for the $10 group) were found.
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cluster designs that can be used to improve their 
efficiency.
Why cluster trials are often used in research set 
in LMICs
Cluster trials can be useful in LMIC settings for several 
reasons. Cluster randomisation can potentially reduce 
treatment contamination between intervention and 
control groups.4,10,27 For instance, clinical trials of 
nutritional interventions that are set in small, rural 
communities can appropriately and effectively use this 
design, since masking of nutritional interventions at the 
individual level might not be possible and treatment 
contamination could occur by food sharing between 
community members randomly assigned to different 
groups. If participants were individually assigned to the 
control group, they could potentially receive food 
supplements intended for the intervention group, 
resulting in a partial effect of the intervention in the 
control group, with or without a lesser effect in the 
intervention group. In such a scenario, an underlying 
true effect of the nutritional intervention is less likely to 
be detected or might be blunted. As a result, several 
cluster trials have had notable successes at improving 
health outcomes that would otherwise be difficult to 
assess with individual RCTs. These (non-exhaustively) 
include Ebola vaccination,28 hypertension management,29 
and overall childhood mortality.7 In these cases, and 
in many more, careful planning and consideration of 
the research question and mechanistic principles of 
treatment has led to improved understanding across 
a multitude of diseases, particularly in resource-
constrained settings.
In such a scenario, unless the sample size calculation 
accounts for contamination, the effect of the nutritional 
intervention is unlikely to be detected with the collected 
data. Increasing the degree of treatment contamination 
can reduce the statistical power of a given two-arm 
individual RCT (figure). Similar findings of the 
substantial risk of false-negative results have been shown 
in the literature.27,30
By contrast, if the intervention can be delivered at the 
level of the individual, it might be preferable to conduct an 
individual RCT with a larger sample size, rather than by 
cluster randomisation.31 The delivery of an intervention at 
an individual level is particularly appropriate in 
circumstances in which there is only a modest risk of 
contamination, there is a large intracluster correlation 
(ICC), or the cluster sizes are large.27 Sample size 
requirements to reach 80% statistical power with varying 
degrees of treatment contamination for a two-arm 
individual RCT and for a two-arm cluster trial without any 
contamination are shown in the figure and appendix (pp 
2–3). The sample size required for an individual RCT is 
smaller than that for a cluster trial with a modest degree of 
treatment contamination. For instance, when 15% relative 
risk reduction is expected at a baseline event rate of 20%, 
an individual RCT without contamination requires a 
sample size of 2069 per trial arm, compared with 2855 in 
a cluster trial. The individual RCT is more efficient than a 
cluster trial, as long as treatment contamination is 
below 18%. The contamination threshold can increase 
with larger cluster sizes or ICCs, or both, when treatment 
effects are larger.
External validity
Another reason for the popularity of cluster trials 
over individual RCTs is the perceived improved external 
validity (or generalisability).4,32 This perception of 
improved external validity is particularly prevalent when 
interventions engage large cluster groups, such as 
health districts. Global health research often aims to be 
pragmatic, to answer whether interventions can work 
under real-world conditions, and to be applicable to a 
diverse population.33,34 Many health challenges in LMIC 
contexts are well addressed by these aims. Cluster 
trials provide a unique approach in infectious disease 
interventional research, facilitating assessment of 
population-level efficacy in the presence of herd effects. 
Scaling of interventions is also reported as a benefit 
of cluster trials. For instance, trials of interventions 
administered at the community level more closely 
resemble how a scaled intervention would be distributed 
logistically. Further, cluster trials frequently cover the 
entire community to provide a better estimate of group 
benefit. A successful example of a community-based 
scale-up interventional trial is the Control of Blood 
Panel 3: The THRio study (NCT00107887): a stepped-wedge cluster trial for 
tuberculosis screening and preventive therapy 
The tuberculosis/HIV in Rio de Janeiro (THRio) study was a stepped-wedge cluster trial 
that aimed to evaluate the role of staff training in tuberculosis screening, tuberculosis skin 
tests, and use of isoniazid preventive therapy versus standard of care in HIV clinics in Rio 
de Janeiro, Brazil.23–26 Of the 29 HIV clinics (clusters) enrolled in this stepped-wedge trial, 
two (7%) clinics were randomly assigned to the intervention group every 2 months 
between September, 2005, and August, 2009. A coefficient of variation of 0·2 for 
tuberculosis incidence rates was used to calculate the sample size, assuming a control 
event rate of 3·65 events per 100 person-years and a 40% reduction in treatment effect 
size (ie, of 2·20 events per 100 person-years in the intervention group) to reach a 5% type 
I error rate and 80% statistical power. The primary analysis used an intention-to-treat 
analysis, including all patients who were eligible to receive the tuberculosis skin test or 
isoniazid preventive therapy (n=12 816 patients).
Compared with the control, the intervention showed an adjusted hazard ratio of 0·73 
(95% CI 0·54–0·99) for tuberculosis incidence and an adjusted hazard ratio of 0·69 
(0·57–0·83) for the composite outcome of incidence of and death from tuberculosis (with 
adjustments made for age, sex, use of highly active antiretroviral therapy at baseline, and 
time-varying CD4 concentration). Additionally, the rate of tuberculosis skin testing 
showed an improvement from 19 events per 100 person-years observed during the 
control period to 59 events per 100 person-years in the intervention period, and the rate 
of isoniazid preventive therapy improved from 36 events per 100 person-years to 
144 events per 100 person-years between the control and intervention periods.
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Pressure and Risk Attenuation study, set in Bangladesh, 
Pakistan, and Sri Lanka, which was a multi-part 
intervention delivered by community health workers to 
manage hypertension. A strength of this study was that 
the programme was focused on outreach by community 
health workers rather than on guiding communities to 
treatment centres and other settings outside of their 
communities.29 
Many individual RCTs are carried out with specific types 
of patients under controlled conditions, with strict 
inclusion and exclusion criteria (mechanistic individual 
RCTs) for improved internal validity, but often this internal 
validity is achieved at the expense of external validity 
(explanatory trials). This type of trial design has been 
criticised for not reflecting real-world conditions and 
having unrealistic clinical populations, leading to poor 
external validity.35–37 As such, evidence from cluster trials is 
appealing to policy makers because their implementation 
can more accurately reflect the real-world roll-out of novel 
interventional strategies. However, related approaches, 
such as pragmatic individual RCTs, can be carried out 
with diverse groups of participants to evaluate the 
effectiveness of interventions in real-life routine settings 
without the use of cluster trial designs.36
Acceptability, adherence, and ethical considerations
Cluster trials are argued to have higher acceptability 
by the communities receiving the interventions and 
improved adherence to the allocated intervention 
compared with individual RCTs.4,10 When treatment 
group masking is not possible, individual randomisation 
can create resentment among individuals randomly 
assigned to the control group, particularly if the given 
trial aims to evaluate the role of a desired intervention, 
such as cash transfers.4 Cluster trials could be more 
appropriate to evaluate these types of interventions 
because it might be unfair and unethical for certain 
individuals to receive financial aid while their peers 
knowingly do not.4,38
Cluster trials are conceptually able to improve 
acceptability and adherence to an assigned intervention, 
but these qualities are rarely assessed and reported 
in cluster trial publications.32,39 Improved reporting on 
such topics could strengthen these discussions. Some 
shortcomings have been discussed with regard to 
assessments of cluster trial acceptability from previous 
work. In global health research, acceptability at the 
community level is often assessed by village leaders, who 
might not accurately speak on behalf of the individuals.38 
This approach could affect the adherence of individual 
members of the cluster, although it is important to note 
that previous reviews of adherence in cluster trials 
have indicated poor reporting of this characteristic, 
complicating the interpretation of results.39
Practical advantages
Other reasons for the use of cluster randomisation 
include practical advantages, such as administrative 
convenience, lower implementation costs, and improved 
acceptability and compliance compared with individual 
RCTs.4,39,40
Trial planning challenges for cluster trials in 
global health
A specific consideration in cluster trials is related to the 
interplay between individuals and clusters. In cluster 
trials, the responses of individuals within each cluster are 
often correlated with respect to environmental, socio-
economic, and other specified or non-specified prognostic 
factors.40 This correlation leads to an increase of within-
cluster correlation and between-cluster variability in 
the health outcomes concerned.4 In turn, the overall 
variability of the observed treatment effects is inflated, 
resulting in statistical inefficiency that might require a 
much larger sample size compared with individual RCTs.41 
Cluster trials that fail to account for the effects of clustering 
in the analysis will result in inflated type I error rates.10,14 
As such, it is vital to emphasise the importance of 
including these characteristics in any statistical analysis 
plan and subsequent publication. There is often a 
misunderstanding among investigators and funders that 
cluster trials facilitate enrolment of a larger number of 
participants (more than 1000) than individual RCTs and 
that these large sample sizes therefore might be more 
representative or provide better precision.42,43
The effects of clustering on the sample size can be 
expressed through the design effect, a statistical measure 
of relative inflated variance due to cluster randomisation.4 
For instance, a cluster trial with a design effect of 3 would 
require triple the sample size of an individual RCT. 
Calculating the design effect requires an estimated value 
of the ICC or coefficient of variation. ICC measures the 
similarity of the individual responses from within the 
cluster, compared with the responses from different 
clusters.4,44,45 As the ICC value decreases, so does the 
required sample size for statistical power.45,46 The 
Figure: Effects of treatment contamination on statistical power of a two-arm individually randomised 
clinical trial assessing a dichotomous outcome and on the sample size required for 80% power
(A) Effect of treatment contamination on power of individual randomised clinical trials. (B) Sample size per trial arm 
required for 80% power in an individual randomised clinical trial, with contamination (solid lines) and the degree of 
contamination in an individual randomised clinical trial that requires a sample size identical to that of a cluster trial 
without contamination (dashed lines) shown. Detailed assumptions are provided in the appendix (pp 2–3).
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coefficient of variation (a standardised measure of the 
between-cluster variance) can also be used to express 
the effects of clustering to calculate the sample size of 
cluster trials, and is directly related to the sample size.4
For both cluster trials and individual RCTs, investigators 
must prespecify characteristics such as effect sizes 
and loss-to-follow-up rates. Prespecification of trial 
parameters is an added challenge in cluster trials because 
entire clusters might be lost to follow-up, and it might be 
difficult to make such assumptions at the start of the 
study. Availability of a sampling framework (the existing 
number of clusters to choose from) for randomisation 
and the size of the cluster all add to the complexity of 
sample size calculation when compared with individually 
randomised trials.47 As such, pretrial activities assessing 
the true number of available clusters, running scenario 
analyses, interim evaluations and, where appropriate, 
clinical trial simulation can assist in developing 
contingency plans for these challenges.
Number of clusters randomised within the trial
Knowledge of the number of clusters available for 
randomisation is important for trial planning for a 
multitude of reasons. Randomisation might help to 
ensure that there is balance in observable and non-
observable prognostic factors between groups being 
compared, but balance in prognostic factors is only 
retained when there are a large number of clusters that 
are being randomised. There are often geographical and 
other practical constraints that limit the number of 
clusters that can be enrolled in a given clinical trial, 
particularly in LMICs. For instance, there might be only a 
small number of hospitals in a region of interest, or there 
might only be enough funding to enrol a small number 
of clusters. The number of clusters should be adequate, 
to minimise the chance of imbalance; although, this 
number must also be considered in relation to the 
potential for overpowering the trial.48,49 Notably, although 
increased cluster numbers might generally improve 
balance, specific plausible variables of interest (eg, 
socioeconomic status and development parameters) must 
also be adequately accounted for with increased cluster 
numbers. As such, careful evaluation of cluster sizes and 
local restrictions (eg, the total number of schools or 
communities available) is essential for effective trial 
planning.
Confounding resulting from imbalance can result in 
inflated risks of false-positive and false-negative findings. 
Although statistical techniques can adjust for baseline 
covariates in cases of imbalance, these techniques still 
require the availability of a relatively large number of 
individual patient-level covariates, which might not be 
available. The use of a large number of clusters is still 
preferred, such that randomisation can ensure balance in 
terms of both observable and non-observable factors 
between groups being compared.50 Finally, it is important 
to recognise that power in a cluster trial depends to 
a greater extent on the number of clusters than the cluster 
sizes: a hypothetical cluster trial with hundreds of thousands 
of participants but only a few clusters might never reach 
80% statistical power, owing to the diminishing returns 
that increasing participant numbers relative to increasing 
cluster numbers provides for cluster trials.48
Cluster sizes and their variability
Cluster sizes and their variability are important limiting 
factors for cluster trials. The cluster size (ie, the number of 
participants per cluster) required to reach sufficient 
statistical power depends on the number of clusters 
available for randomisation. When the number of clusters 
increases, fewer participants per cluster are ideal, and 
when only a small number of clusters are available, a 
larger number of participants per cluster is required.4,46 
Although statistical power might be improved by 
increasing the total sample size, increasing the sample 
size can have diminishing returns on statistical power, 
especially when the ICC is large.49 Increasing the sample 
size becomes a particular challenge when communicating 
the results of cluster trials. There is often a temptation to 
relay the significance of a trial in relation to the total 
sample size of the trial. In cluster trials, substantial 
numbers of patients are often recruited, but each 
individual’s respective contribution to the statistical power 
of the trial is unclear without reference to the total cluster 
size and associated variability.
In addition to cluster sizes, it is important to consider 
the variability in sizes for trial planning because cluster 
size variability can negatively affect the statistical 
power.51,52 Compared with cluster trials with equal cluster 
sizes, cluster trials with highly unequal cluster sizes 
require larger sample sizes to reach the same statistical 
power.46 In fact, the required sample size increases as the 
cluster size variability increases, because smaller clusters 
will have less precise treatment estimates than those 
from larger clusters.46 Cluster size variability might cause 
imbalances between intervention and control groups that 
could be difficult to adjust for with the use of statistical 
analyses.51 In instances for which allocation concealment 
is not possible, cluster size variability and baseline 
imbalance might result from selection or attrition biases, 
or both.53
Cluster size variability is common in community trials 
where, based on eligibility, there might be an under-
recruitment of individuals in some of the clusters or an 
over-recruitment in the other clusters, or both.51 If 
recruitment is delayed due to under-recruitment in some 
regions, there might be a perception that recruiting more 
participants from other clusters will help to balance 
the trial. However, this alteration might exaggerate the 
cluster size variability or lower statistical power further 
and introduce biases, affecting both the internal validity 
and generalisability of the trial findings.51 The overall 
effect of this variability on subsequent statistical power 
and operational charac teristics can be variable,54 and it is 
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frequently challenging to formally assess the effects of 
variable cluster sizes, owing to poor reporting of key trial 
characteristics within the literature.9
Anticipating the clustering effects
Anticipating the effects of clustering can be challenging. 
There is often no accurate estimate of ICC, and as a result, 
the ICC is often ignored or a nominal value (typically 0·05) 
is used for sample size calculations of cluster trials.11 Even 
with accurate assumptions about the underlying treatment 
effects and baseline risks, which is also required for 
individually randomised trials, a cluster trial might be 
underpowered with an underestimated ICC assumption 
or, on rare occasions in which the ICC is overestimated, 
the trial can end up recruiting excessive numbers of 
clusters and sample sizes. To facilitate future research 
activities and improve the interpretation of cluster trials, 
reporting of observed ICC values is crucial. Reporting of 
ICC is currently recommended in the Consolidated 
Standards of Reporting Trials extension for cluster trials 
(item 17a), but this recommendation is limited to the 
primary outcome only, and ICC is specific to each outcome, 
creating challenges with interpreting secondary outcomes.9
Because a large number of clusters are usually required 
to achieve balance between intervention and control 
arms, cluster trials in global health research often involve 
multiple geographical regions across several countries. 
When carrying out a cluster trial across multiple regions, 
there are frequently substantial disparities in disease 
burden between geographical settings. These disparities 
can contribute to high variability between different 
clusters and thus inflate the ICC. For instance, recent 
work has shown substantial subnational disparities in the 
prevalence of childhood stunting in several African 
countries, with national stunting prevalence varying by 
more than five times between nearby countries.55 
There can also be substantial disparities in disease 
burden within a single country, making the implemen-
tation of single-nation cluster trials difficult in global 
health research. For example, in Rwanda, there are 
disparities in the prevalence of childhood stunting 
between different districts across Rwanda (appendix 
p 4).56 Although the stunting prevalence in Kigali (the 
capital city) is low (22%), the prevalence of stunting is 
much higher in four nearby provinces (ie, the western, 
northern, southern, and eastern provinces). Geographical 
disparities in disease burden can pose challenges when 
trying to estimate the clustering effects as part of trial 
planning of cluster trials in global health research. 
Another example of the influence of geography on trial 
outcomes is cord cleansing with chlorhexidine, which in 
settings of a high incidence of home-birth deliveries 
(around 75%) showed marked improvements in neonatal 
mortality.57 When repeated in settings of a high incidence 
of facility-birth deliveries (around 65%), minimal 
improvements were noted, emphasising the importance 
of cluster selection.58
Maintaining internal validity
As briefly mentioned, cluster trials are often preferred 
in global health research for their pragmatism and 
generalisability, but at a compromise of internal validity.4,42 
Balancing for external validity and internal validity needs 
careful consideration. Although selection bias is possible 
in individual RCTs, such biases can be more problematic 
for cluster trials because attrition bias can occur at both the 
individual and cluster levels.42 For instance, for a hospital-
based cluster trial, doctors acting as recruiters for the 
hospital might be less motivated to recruit patients if their 
hospital was randomly assigned to the control group than 
doctors in hospitals allocated to the intervention group.
There are several strategies to minimise selection bias 
for cluster trials, covering both individual-level and cluster-
level selection biases.42,43,59 Bias from study recruiters can 
be minimised by use of an independent recruiter who is 
masked to group allocation. Selection bias at the individual 
level can be minimised by identifying and obtaining 
consent from participants before cluster randomisation,60 
or by offering delayed assignment to the other group (eg, 
at the end of the study).
Ethical challenges
In addition to the aforementioned statistical issues, cluster 
trials can raise difficult ethical questions for global health 
research. A useful resource for researchers interested in 
these challenges is the Ottawa Statement on Ethical 
Design and Conduct of Cluster Randomised Trials.61 In 
essence, cluster trials share many ethical challenges with 
individual RCTs, although there are several unique design 
features which warrant a more detailed review.
In individual RCTs, obtaining informed consent from 
each individual study participant is usually required; 
however, in cluster trials, informed consent might only 
be obtained from selected members of the community if 
the interventions can only be administered at the 
community level.38 The role of such community 
gatekeepers in cluster trials is a contentious topic in 
medical ethics; for further discussion, readers are 
encouraged to review Gallo and colleagues’ work 
reviewing this specific issue.62
For interventions that can be evaluated by use of 
individual RCTs, it is important that these interventions 
have already shown their clinical utility and pose minimal 
risks to the population before being considered for cluster 
trials, given that these designs often result in large 
numbers of participants. Additionally, it is important to 
consider the potential ethical issues of withholding a 
given intervention from certain communities and not 
others, because this can contribute to the perception of 
health inequity among trial participants and between 
communities.38 As data accumulate in a cluster trial, or if 
policy changes occur during the implementation of the 
trial, there might be a strong obligation to modify or even 
stop the study if the study intervention is unsafe or 
ineffective, or both.38
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Assessment of cluster trial planning practices in 
global health
To provide some examples of cluster trial planning 
practices in global health research set in LMICs, we did 
a focused literature review of LMIC-based cluster trials 
that have been published between Jan 1, 2010, and Nov 1, 
2018 for three key areas of global health research: 
MNCH, WASH, and malaria. We evaluated the cluster 
trial planning practices in global health research set in 
LMICs by assessing the reported assumptions used to 
derive sample size estimations among the 80 eligible 
cluster trials in these selected disease topics (table). The 
search terms, eligibility criteria, and details of our 
analytical approaches for this assessment are provided 
in the appendix (pp 5–27).
Although not unique to cluster trials or global health 
research, cluster trial sample size calculations are often 
done with higher baseline event rates, overly optimistic 
treatment effect sizes, and lower clustering effects than 
those that are actually observed later. Among the cluster 
trials on the topics of MNCH, WASH, and malaria, we 
identified that a large proportion of these trials used 
higher rates of baseline event rates and anticipated 
treatment effects for sample size calculations than those 
that were later actually observed. Of the 80 included 
trials, 62 (78%) of the trials were undertaken with binary 
or count data primary outcomes. Of the 80 trials assessed, 
45 (56%) reported data on assumed baseline risks. Where 
presented, 11 (24%) of 45 trials reported a baseline risk or 
rate at least 50% smaller than anticipated. The proportion 
of overestimates varied across the included topics, with 
MNCH representing the lowest proportion (11%), and 
malaria (29%) and WASH (25%) trials representing 
similar proportions. Three (7%) of the 45 trials had 
overestimated the baseline risk or rate during planning 
by at least 50%.
In examining treatment effect sizes, we observed 
that 27 (51%) of 53 of the included trials reported 
overestimation of treatment effects, in which the observed 
effect size was at least 50% smaller than the assumed 
effect size for sample size calculations. Higher proportions 
of overestimation (ie, an effect size less than 50% of the 
assumed effect size) were noted in MNCH trials (70%) 
relative to malaria (48%) and WASH (43%) trials. It was 
more difficult to assess the cluster trial planning practices 
in terms of clustering effects because the ICC was often 
inadequately reported. Of 80 cluster trials identified, only 
13 trials (16%) reported on both planned and observed 
ICC. Of the 13 trials that reported both planned and 
observed ICCs, 9 (69%) noted a difference of 50% or 
greater than assumed values. Overall, 8 (18%) of 45 trials 
showed an overestimation of baseline effects at the same 
time as an overestimation of treatment effects. Similarly, 
12 (27%) of 45 trials reported overestimations of treatment 
effects and either ICC or baseline effects.
There are many possible reasons for the high 
frequency of erroneous assumptions used for cluster 
trial planning in terms of baseline event rates, treatment 
effects, or clustering effects. Erroneous assumptions 
used, particularly for treatment effect sizes, might be 
due to optimism held by the trial investigators.
Although we report on the widespread mismatch in 
anticipated baseline event rates and treatment effects 
relative to those that were later actually observed in the 
global health cluster trials, this disparity was not 
frequently discussed in the publications. One publication 
noted that their substantially lower observed base event 
rate for malaria prevalence was almost certainly due to a 
drought that coincided with the initiation of their trial.63 
Another malaria trial noted that stopping of one outcome 
measurement of parasite detection was due to the low 
event rate of parasite carriage in enrolled clusters,64 
whereas two other trials noted that their planned sample 
size was increased to retain appropriate statistical 
power.65,66
Alternative approaches and designs for cluster 
trials in global health
Interim evaluations
Cluster trials usually have a single-stage approach with a 
fixed trial design, in which all clusters are enrolled and 
randomised simultaneously and then observed for a 
fixed duration. Instead of using a single-stage approach, 
it might be beneficial to use a multi-stage approach, in 
which interim data are used to estimate the key trial 
parameters and calculate the sample size again (sample 
All (n=80) MNCH (n=23) Malaria (n=32) WASH (n=25)
Proportion of trials with binary or count outcome as the primary outcome 62 (78%) 10 (43%) 32 (100%) 20 (80%)
Binary or count baseline effect was >50% smaller than predicted 11/45 (24%) 1/9 (11%) 7/24 (29%) 3/12 (25%)
Binary or count treatment effect was meaningfully different to predicted value* 27/53 (51%) 7/10 (70%) 14/29 (48%) 6/14 (43%)
Intracluster correlation or coefficient of variation was meaningfully different to 
predicted value†
9/13 (69%) 4/5 (80%) 5/6 (83%) 0/2 (0%)
Data are n (%) or n/N (%). MNCH=maternal, newborn, and child health. WASH=water, sanitation, and hygiene. *Observed effect of <25% relative risk reduction or <2% absolute 
differences for binary outcomes. †A difference of >50% relative to the originally planned value, regardless of direction of effect. The substantially smaller denominator value is 
because of the small (16%) number of trials that reported both a planned and an observed intracluster correlation or coefficient of variation.
Table: Assessment of sample size calculation practices for cluster trials in global health: baseline event rate, treatment effect size, and intracluster 
correlation assumptions across MNCH, malaria, and WASH trials
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size reassessment).67 To determine the timing of the 
interim analysis, a sufficient number of observations 
from the enrolled clusters are required for a reliable 
estimate of the ICC at the interim analysis.68
For instance, if a sample size reassessment shows that 
the new requirements in sample size or in the number 
of clusters exceed what is realistically feasible, a decision 
to stop the trial might be considered. The use of a multi-
stage approach with preplanned interim evaluation 
plans can represent an appealing mechanism to 
minimise the risks of false-negative findings for cluster 
trials in which uncertainty exists over the planned trial 
parameters.69 High-profile cluster trials have already 
integrated such methodologies, such as early stopping 
rules for efficacy and futility,7 as well as preplanned rules 
for stopping of treatment arms in isolation for multiarm 
trials.70
Statistical methods for imbalance 
It is often assumed that randomisation can remove 
selection bias and produce groups that are comparable in 
terms of both measurable and unmeasurable factors. 
However, in cluster trials, this assumption might not 
hold true, especially when there is a low number 
of clusters available. The potential risk of baseline 
imbalance between the intervention and control groups 
can be substantial when there is a small number of 
clusters available.40 If data are available for important 
cluster-level or individual-level covariates, covariate-
constrained randomisation could be a useful method to 
prevent imbalance in studies for which there is only a 
small number of clusters.71
In covariate-constrained randomisation, investigators 
determine criteria for balance across key baseline 
covariates of interest. All possible configurations of 
allocations of participating clusters can then be 
generated to subsequently be narrowed down to a 
smaller list of potential allocations by use of the 
prespecified criteria for balance. Then, the actual 
allocation would be chosen randomly from this 
narrower list to maintain an appropriate level of 
randomness in this selection process. When using 
covariate-constrained randomisation, it is important to 
prespecify the key covariates and the criteria for balance 
before generating all possible allocation schemes. It is 
also important not to apply overconstraint through 
strict balancing requirements because this scenario 
might result in very few possible allocations and, thus, 
not represent true randomisation.71 Covariates used in 
the constrained randomisation should be adjusted for 
in the statistical analyses, to avoid inflation of type I 
error rates.72
Stepped-wedge designs
A stepped-wedge design is a type of cluster trial design in 
which all clusters start in the control condition but 
gradually cross over to the intervention condition, in 
randomised sequence, until every cluster included in the 
trial has received the intervention of interest.73 This design 
differs from the conventional parallel design that is most 
often used in cluster trials because, in parallel design, 
clusters are randomly assigned to intervention or control 
groups; not all clusters receive the intervention of interest 
before the cluster trial with a parallel design is completed.73
Stepped-wedge designs can help to minimise some of 
the drawbacks of parallel arm designs under select 
circumstances. For instance, stepped-wedge designs 
might be useful when there is only a small number of 
clusters available. Stepped-wedge designs can often reach 
the same statistical power as the parallel cluster trial 
design but with fewer clusters, particularly when ICC 
values are greater than 0·03.73,74 The reason stepped-wedge 
designs might require fewer clusters is because each 
cluster is exposed to both control and intervention 
conditions; hence, the estimation of treatment effects in a 
stepped-wedge trial can benefit from the use of within-
cluster comparisons. For example, using the results of a 
previous cluster trial,75 Hooper and Bourke74 have shown 
that a stepped-wedge design consisting of two, three, or 
four regular intervals (the so-called steps), in which a 
group of clusters are randomised to cross from the control 
to the intervention, reduced the required number of 
clusters to reach appropriate statistical power by 23%, 
54%, and 66%, respectively. Another advantage of stepped-
wedge designs is less sensitivity of statistical power to the 
ICC value. Although the statistical power is reduced in 
both parallel and stepped-wedge trial designs when an 
underestimated ICC value is used for sample size 
calculation, the statistical power for the stepped-wedge 
design is less affected than that of the parallel design.73 
However, stepped-wedge cluster trials increase statistical 
complexities compared with parallel cluster trials in that 
correlation coefficients are more complex: not only do 
correlations within the same cluster need to be accounted 
for, correlations in repeated measures from the same 
cluster over time also need to be factored in.
Although stepped-wedge trials offer promise when high 
numbers of individuals per cluster are available, these 
trials do have drawbacks. Even though increased steps can 
provide improved statistical properties, this approach also 
requires more measurements (and, as such, a potentially 
longer trial duration) per cluster compared with parallel 
designs.76 As such, there is an important need during trial 
planning to balance the number of steps and associated 
sample size reduction against increased operational costs 
and trial duration with increased numbers of observations, 
and whether there are any associated ethical implications 
with this. The associated operational complexity of 
coordinated calendar timing for stepped-wedge designs 
must also not be underestimated. Potentially as a 
consequence of this underestimation, authors have 
previously noted that approximately half of stepped-wedge 
trials failed to reach their planned sample size and 
implementation schedules.77
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Conclusion
Evaluating whether interventions have an effect at the 
population level is challenging. The most commonly 
applied method for evaluating population-level effects—
ie, the cluster trial—has complications that can be 
difficult to overcome. When carried out successfully, 
these trials represent a unique and powerful investi-
gational tool, but careful considerations should be made 
ahead of their implementation. Cluster trials are typically 
much larger than individual RCTs, so these trials require 
considerably larger financial resources, posing challenges 
for LMICs and research funding bodies that are already 
stretched. More rigorous pretrial estimation processes, 
alongside integration of novel trial methodologies, might 
reduce the prevalence of these problems and minimise 
the number of participants recruited, the money spent, 
and the time lost on trials that do not have the necessary 
characteristics to draw meaningful conclusions.
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